AnaptysBio (ANAB) isn’t your traditional biotech play. Essentially, it is a low-overhead royalty-management company formed around 2 drugs: Jemperli (partnered with GSK) and imsidolimab (partnered with Vanda Pharma).
Here’s the relevant backstory. In 2014, ANAB signed a collaboration and exclusive licensing agreement with the biotech company Tesaro, resulting in the development of Jemperli, a blockbuster (>$1B global sales) therapeutic immuno-oncology antibody, currently approved for endometrial cancer.
In this deal, ANAB receives tiered royalties that step up with higher sales ([link](https://ir.anaptysbio.com/static-files/d12275b2-d99f-4a2e-8697-de3a6969ec68)).
In 2019, GSK acquired Tesaro and subsequently began running clinical trials which combined one of their cancer treatments with either Jemperli or Keytruda (a direct competitor of Jemperli from Merck). By doing so, Tesaro (now a GSK subsidiary) violated their exclusive licensing agreement with ANAB.
In a preemptive legal maneuver, GSK sued ANAB, claiming that ANAB’s accusations represented a breach of contract. However, in April 2026 the Delaware courts ruled heavily in ANAB’s favor and dismissed GSK’s claim to reduce ANAB’s royalty rates.
Tailwind Possibility #1: Legal settlement with GSK
The courts are now adjudicating ANAB’s counter claim of contract breach against GSK. Their argument is that Tesaro is essentially a shell company and that GSK is wholly responsible for the breach of contract and thus is financially responsible.
The ideal legal outcome for ANAB is that rights to Jemperli fully revert to them. With possession of a clinically approved drug that is generating >$1B in sales per year, they would be able to partner with a different big pharma player for significantly improved financial terms (think large upfront cash payment and a larger split of sales).
A more probable outcome is that the trial gives ANAB immense leverage to force GSK into a massive financial settlement and/or enhanced royalty terms. Both outcomes should significantly boost ANAB’s stock price.
In the worst case scenario the court does not rule in ANAB’s favor but the downside is limited as previous rulings block GSK from reducing ANAB’s current royalty structure.
The trial is currently in session (July 14-17, 2026) and the outcome should be a major catalyst for the stock price.
Tailwind Possibility #2: Expanded Indications for Jemperli
Jemperli is currently in clinical trials for additional indications, including several subtypes of rectal cancer, colon cancer, and head-and-neck squamous cell carcinoma.
There will be upcoming clinical trials readouts in H2-2026 (for rectal cancer; AZUR1 trial) and Q4-2026 (for colon cancer; AZUR4 trial.
Needless to say, positive clinical data would be a tremendous tailwind for ANAB. Especially because ANAB would earn a higher royalty rate with increased sales numbers.
While no one can predict the outcome of these clinical trials, Jemperli is de-risked significantly as a drug from a safety and efficacy standpoint because it is already approved for use in a different cancer type (endometrial cancer).
Tailwind Possibility #3: Imsidolimab approval?
We haven’t talked about their other drug: Imsidolimab. The relevant date for this one is Dec 12th, 2026. That is when the FDA will complete its review of whether imsidolimab can be marketed and sold in the U.S. for the treatment of Generalized Pustular Psoriasis. If approved, this will trigger additional milestone payments to ANAB, further bolstering its cash flow.
Tailwind Possibility #4: Paydown of the Sagard loan
This one is a longer dated tailwind but worth mentioning. ANAB is obligated to pay Sagard $600M for a loan that helped fund its clinical trials. Recent company filings indicate ANAB anticipates paying off this loan by Q2-2027, which would result in a significant boost to its cash flow and holdings. Whether this is already ‘priced in’ is up for debate, but worth noting here.
ANAB’s potential:
Analysts have a consensus strong buy rating on ANAB. The average 12-month price target is $81-$87, with a high estimate of $140 and a low estimate of $70. Currently ANAB trades at \~$65.
There is unusually high short interest with 25.5% of the shares being shorted (as of July 13th, 2026). The stock has a typical daily trading volume of 600-700,000 shares.
If one or more of these upcoming key positive catalysts materializes, in my opinion the stock would re-rate higher and momentum alone could carry it to the $90s, and potentially >$100 in a relatively short period of time.
I am eyeing the $70 level. There is plenty of overhead supply there and a true breakout of ANAB would require clearing $70 on heavy volume.
I hold shares of ANAB around $65-$66 at the time of this writing. This is not financial advice. Just wanted to share my thoughts on an interesting stock!